InvestmentJun 3, 2026, 08:31 AM
LIXTE Biotechnology Raises $16.57M in Registered Direct Offering
AI Summary
LIXTE Biotechnology Holdings, Inc. announced it has entered into definitive agreements for a registered direct offering with accredited investors, expecting to raise approximately $16.57 million. The offering, priced at market under Nasdaq rules, includes the sale of 2,625,362 shares of common stock and pre-funded warrants at $6.31 per share and $0.0001 per warrant, respectively. This financing is intended to materially strengthen the company's balance sheet, provide flexibility for strategic priorities, and support general corporate purposes and working capital. The company also highlighted the recent appointment of Stuart D. Porter to its Board of Directors.
Key Highlights
- LIXTE Biotechnology entered definitive agreements for a registered direct offering.
- The offering will generate approximately $16,566,027 in gross proceeds.
- It involves the sale of 2,625,362 shares of common stock and pre-funded warrants.
- Offering price is $6.31 per share of common stock and $0.0001 per pre-funded warrant.
- Proceeds will be used for general corporate purposes, working capital, and strategic initiatives.
- The transaction was priced at market under Nasdaq rules.
- Stuart D. Porter, founder of Denham Capital, recently joined the Board of Directors.
Price Impact
More from LIXT